McKesson (MCK, Financial), a leading pharmaceutical wholesaler, experienced a 1.78% drop in its stock price, now trading at $599.55 per share with a trading volume of 341,487 shares and a turnover rate of 0.27%. The stock's amplitude reached 1.86%.
Recent financial reports show McKesson achieved a revenue of $95.294 billion and a net profit of $879 million, with earnings per share of $6.98. The company's gross profit stood at $3.22 billion, and it has a price-to-earnings ratio of 27.54. Among 19 rating institutions, 79% recommend buying, 16% suggest holding, and 5% advise selling the stock.
In the broader medical sales industry, the overall decline was 1.40%. Notable stock movements included significant gains by Synergy Chc Corp., Edap Tms S.A., and 1药网. Meanwhile, stocks like 欧麦斯-麦能医疗, Cosmos Health Inc., and 亨利香恩服务 showed active trading with turnover rates of 0.45%, 0.44%, and 0.43%, respectively. Synergy Chc Corp., Edap Tms S.A., and Cosmos Health Inc. exhibited notable amplitude fluctuations of 32.12%, 7.65%, and 5.10%.
McKesson is one of the top three pharmaceutical wholesalers in the U.S., distributing branded, generic, and specialty drugs to pharmacies, hospitals, and healthcare providers. Alongside Cencora and 嘉德诺健康, McKesson accounts for over 90% of the U.S. pharmaceutical wholesale market. The company also operates in Canada and provides medical-surgical products, equipment, and various pharmacy technology solutions.
